PTC607 / PTC Therapeutics - LARVOL DELTA

First in human study of multiple doses of a novel drug PTC607 to assess its safety and tolerability in healthy participants (ANZCTR) - P1 | N=24 | Completed | Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd | Not yet recruiting ➔ Completed

Trial completion • Huntington's Disease • Movement Disorders

First in human study of multiple doses of a novel drug PTC607 to assess its safety and tolerability in healthy participants (ANZCTR) - P1 | N=24 | Not yet recruiting | Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd

New P1 trial • Huntington's Disease • Movement Disorders

First in human clinical study of a novel drug PTC607 to assess effects of food intake and to compare PTC607 levels, when taken as an oral suspension and tablet formulation. (ANZCTR) - P1 | N=8 | Completed | Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd. | Not yet recruiting ➔ Completed

Trial completion • Trial initiation date • Huntington's Disease • Movement Disorders

First in human clinical study of a novel drug PTC607 to assess its safety and tolerability in healthy volunteers (ANZCTR) - P1 | N=40 | Completed | Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd. | Recruiting ➔ Completed

Trial completion • Huntington's Disease • Movement Disorders

First in human clinical study of a novel drug PTC607 to assess effects of food intake and to compare PTC607 levels, when taken as an oral suspension and tablet formulation. (ANZCTR) - P1 | N=8 | Completed | Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd.

New P1 trial • Huntington's Disease • Movement Disorders